Table 1.
Studies analysing UPR and EMT in clinical samples and/or primary derived cell lines.
| Type of Cancer | UPR Activation | EMT Footprint | Source | Prognosis | Reference |
|---|---|---|---|---|---|
| Breast cancer | active PERK (ATF4 target genes) | EMT gene signature | human breast cancer datasets | NA | [49] |
| active PERK (ATF4 target genes) | EMT gene signature | human breast cancer datasets | increased metastasis | [112] | |
| Colon cancer | active PERK (ATF4 target genes) | EMT gene signature | human colon cancer datasets | NA | [49] |
| Colorectal carcinoma | IRE1 | E-cad, N-cad | CRC tumour tissues and CRC cell lines | shorter overall survival | [113] |
| GRP78 | β-catenin | CRC tumour tissues | NA | [50] | |
| Gastric cancer | active PERK (ATF4 target genes) | EMT gene signature | human gastric cancer datasets | NA | [49] |
| Glioblastoma | IRE1/XBP1 axis | VIM, ZEB1, TGFβ2 | human GBM cancer datasets and primary derived GBM cell lines | shorter overall survival, increased tumour aggressiveness | [106] |
| Hepatocellular carcinoma | XBP1 | VIM, E-cad | HCC tumour tissue | increased tumour size, increased metastasis | [114] |
| Lung cancer | active PERK (ATF4 target genes) | EMT gene signature | human cancer datasets | NA | [49] |
| IRE1, PERK | ZEB1, SNAI2, SNAI1 | LAC tumours | NA | [115] |
CRC: colorectal carcinoma; GBM: glioblastoma; HCC: hepatocellular carcinoma; LAC: Lung adenocarcinoma; NA: not analysed.